Brillanz Pharma Private Limited
About Brillanz Pharma Private Limited
Data last updated:
Brillanz Pharma Private Limited is a private limited company based in Kamothe, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 08 February 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U74999MH2017PTC290928. Its GSTIN is 27AAHCB0534C1Z7 (Maharashtra).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Prannoti Hemant Mote and Deepali Manoj Tarate.
Its last annual general meeting (AGM) was held on 28 September 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office is at Fl – D/303 Satyakunj Com Plot No.41&42 Sector – 3, Kamothe, Maharashtra, India – 410209.
As per the financials filed for FY 2023, the company reported a revenue of ₹1.94 Lakh, a decline of 59% compared to the previous year. For the same year it recorded a net profit of ₹12,597 (net margin 6.5%) and EBITDA of ₹13,784 (EBITDA margin 7.1%). Revenue has declined at a compounded annual rate (CAGR) of 32% over three years and 1% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Brillanz Pharma Private Limited's registered office is in Kamothe, Maharashtra. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressFl – D/303 Satyakunj Com Plot No.41&42 Sector – 3, Kamothe, Maharashtra, India – 410209
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Brillanz Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Brillanz Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Brillanz Pharma Private Limited, buy the company report.
Financials of Brillanz Pharma Private Limited
FY 2023 filings availableBrillanz Pharma Private Limited reported revenue of ₹1.94 Lakh (down 59% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 1% over five years, including a 59% fall in the latest year. EBITDA rose 115% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹13,784 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹12,597 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 7.1% | ||||
| Net Profit Margin | 6.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Brillanz Pharma Private Limited, buy the company report.
Board of directors of Brillanz Pharma Private Limited
Brillanz Pharma has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Prannoti Hemant Mote | Director | 08 Feb 2017 | 9 Years 8 Months | Current |
| Deepali Manoj Tarate | Director | 08 Feb 2017 | 9 Years 8 Months | Current |
Peer comparison
Brillanz Pharma Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Apotheca Pharmaceuticals Private Limited | ₹1.98 Lakh (FY 2024) | -46.0% | Hyderabad, Telangana, India | |||
| Malabar Organics Ltd | ₹1.95 Lakh (FY 2022) | 36.0% | Koyilandy, Kerala, India | |||
| Brillanz Pharma Private Limitedthis company | ₹1.94 Lakh (FY 2023) | ₹12,597 | 6.5% | -59.0% | Kamothe, Maharashtra, India | |
| Emsons Organics Limited | ₹1.92 Lakh (FY 2016) | -26.0% | Rajpura, Punjab, India | |||
| Chemnex Lifesciences Private Limited | ₹1.91 Lakh (FY 2023) | -36.0% | Borivali, Mumbai, Maharashtra, India |
To see the full peer comparison of Brillanz Pharma Private Limited, buy the company report.
Auditor
Brillanz Pharma Private Limited is audited by A V PARMAR & ASSOCIATES for the financial year 2018.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| A V PARMAR & ASSOCIATES | FY 2018 | 143428W |
Shareholding
The shareholding of Brillanz Pharma Private Limited is on record for 2 financial years, the latest being FY 2018, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2018 | FY 2017 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Brillanz Pharma Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Brillanz Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Brillanz Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Brillanz Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAHCB0534C1Z7 | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Brillanz Pharma Private Limited, buy the company report.
Recent activity
Brillanz Pharma Private Limited has 2 board changes on record since 2017: 2 appointments. The latest: Deepali Manoj Tarate was appointed as Director on 08 Feb 2017.
Frequently asked questions
Brillanz Pharma is an active private limited company based in Kamothe, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 08 February 2017 (9+ years old) and is registered under CIN U74999MH2017PTC290928.
Brillanz Pharma has 2 current directors:
- Prannoti Hemant Mote - Director
- Deepali Manoj Tarate - Director
The latest financial statements of Brillanz Pharma on record with the MCA are for the year ended 31 March 2023. Its last annual general meeting was held on 28 September 2023. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Brillanz Pharma is 27AAHCB0534C1Z7, registered in Maharashtra.
The CIN (Corporate Identification Number) of Brillanz Pharma is U74999MH2017PTC290928. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Brillanz Pharma was incorporated on 08 February 2017, making it 9+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Brillanz Pharma by revenue are Apotheca Pharmaceuticals Private Limited, Malabar Organics Ltd, Emsons Organics Limited, Chemnex Lifesciences Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Deepali Manoj Tarate was appointed as Director on 08 Feb 2017. Prannoti Hemant Mote was appointed as Director on 08 Feb 2017.
The registered office of Brillanz Pharma is at Fl – D303 Satyakunj Com Plot No.41&42 Sector – 3, Kamothe, Maharashtra, India – 410209.
Brillanz Pharma operates in the pharma industry, in the drug formulation and development segment.
The compliance status of Brillanz Pharma is compliant as of 28 July 2026. The company is actively filing with the Registrar of Companies.